{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:15:37Z","timestamp":1693808137142},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4527-y","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T01:37:37Z","timestamp":1529372257000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems"],"prefix":"10.1186","volume":"18","author":[{"given":"Rosa U.","family":"Greasley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek J.","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"issue":"15","key":"4527_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312.","journal-title":"N Engl J Med"},{"issue":"15","key":"4527_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513\u201320.","journal-title":"N Engl J Med"},{"issue":"4","key":"4527_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2217\/fon.11.23","volume":"7","author":"S Oudard","year":"2011","unstructured":"Oudard S. TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011;7(4):497\u2013506.","journal-title":"Future Oncol"},{"issue":"21","key":"4527_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"key":"4527_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, et al. Increased survival with Enzalutamide in prostate Cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"issue":"5","key":"4527_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"3","key":"4527_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"13","key":"4527_CR8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, et al. Increased survival with Enzalutamide in prostate Cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397.","journal-title":"N Engl J Med"},{"issue":"6","key":"4527_CR9","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","volume":"67","author":"N James","year":"2015","unstructured":"James N, et al. Survival with newly diagnosed metastatic prostate Cancer in the \u201cDocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019). Eur Urol. 2015;67(6):1028\u201338.","journal-title":"Eur Urol"},{"issue":"5","key":"4527_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(12)70088-8","volume":"13","author":"ND James","year":"2012","unstructured":"James ND, et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 2012;13(5):549\u201358.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4527_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer. N Engl J Med. 2015;373(8):737\u201346.","journal-title":"N Engl J Med"},{"issue":"6","key":"4527_CR12","doi-asserted-by":"publisher","first-page":"e279-e292","DOI":"10.1016\/S1470-2045(15)70033-1","volume":"16","author":"D Lorente","year":"2015","unstructured":"Lorente D, et al. Sequencing of agents in castration-resistant prostate cancer. The Lancet Oncology. 2015;16(6):e279-e292.","journal-title":"The Lancet Oncology"},{"key":"4527_CR13","doi-asserted-by":"publisher","first-page":"c4078","DOI":"10.1136\/bmj.c4078","volume":"341","author":"TM Trebble","year":"2010","unstructured":"Trebble TM, et al. Process mapping the patient journey: an introduction. Bmj. 2010;341:c4078.","journal-title":"Bmj"},{"issue":"4","key":"4527_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0959-8049(97)10090-9","volume":"34","author":"HJ Andreyev","year":"1998","unstructured":"Andreyev HJ, et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34(4):503\u20139.","journal-title":"Eur J Cancer"},{"issue":"2","key":"4527_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/01635589809514722","volume":"32","author":"P O'Gorman","year":"1998","unstructured":"O'Gorman P, McMillan DC, McArdle CS. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer. 1998;32(2):76\u201380.","journal-title":"Nutr Cancer"},{"key":"4527_CR16","volume-title":"Clinical practice guidelines on cancer cachexia in advanced cancer patients with a focus on refractory cachexia","author":"L Radbruch","year":"2010","unstructured":"Radbruch L, E F, Trottenberg P, Strasser F, Fearon K. Clinical practice guidelines on cancer cachexia in advanced cancer patients with a focus on refractory cachexia. Aachen: Department of Palliative Medicinen\/ European Palliative Care Research Collaborative; 2010."},{"issue":"4","key":"4527_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/annonc\/mdu010","volume":"25","author":"N Timilshina","year":"2014","unstructured":"Timilshina N, et al. Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML? Ann Oncol. 2014;25(4):883\u20138.","journal-title":"Ann Oncol"},{"issue":"3","key":"4527_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejso.2014.11.040","volume":"41","author":"BH Tan","year":"2015","unstructured":"Tan BH, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41(3):333\u20138.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"4527_CR19","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1210\/jc.2013-1115","volume":"98","author":"MH Massicotte","year":"2013","unstructured":"Massicotte MH, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab. 2013;98(6):2401\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"4527_CR20","doi-asserted-by":"publisher","first-page":"e0122047","DOI":"10.1371\/journal.pone.0122047","volume":"10","author":"W Wu","year":"2015","unstructured":"Wu W, et al. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. PLoS One. 2015;10(3):e0122047.","journal-title":"PLoS One"},{"key":"4527_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.eururo.2015.10.047","volume":"69","author":"L Bourke","year":"2015","unstructured":"Bourke L, et al. Exercise for men with prostate Cancer: a systematic review and meta-analysis. Eur Urol. 2015;69:693\u2013703.","journal-title":"Eur Urol"},{"issue":"5","key":"4527_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.euf.2016.08.011","volume":"2","author":"DJ Rosario","year":"2016","unstructured":"Rosario DJ, Greasley R, Bourke L. Castration-resistant prostate Cancer: preservation of quality of life and well-being. European Urology Focus. 2016;2(5):472\u20135.","journal-title":"European Urology Focus"},{"issue":"12","key":"4527_CR23","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1249\/01.mss.0000233803.48691.8b","volume":"38","author":"DA Galvao","year":"2006","unstructured":"Galvao DA, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38(12):2045\u201352.","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"4527_CR24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2009.23.2488","volume":"28","author":"DA Galv\u00e3o","year":"2010","unstructured":"Galv\u00e3o DA, et al. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate Cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28(2):340\u20137.","journal-title":"J Clin Oncol"},{"key":"4527_CR25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4135\/9781412986274.n12","volume-title":"The qualitative researcher\u2019s companion","author":"J Ritchie","year":"2002","unstructured":"Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: The qualitative researcher\u2019s companion; 2002. p. 305\u201329."},{"issue":"2","key":"4527_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"6","key":"4527_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"4527_CR28","unstructured":"NHS England Specialised Commissioning Team. Docetaxel in combination with androgen deprivation therapy for the treatment of hormone na\u00efve metastatic prostate Cancer: NHS England; 2016. Available online. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2016\/01\/b15psa-docetaxel-policy-statement.pdf ."},{"issue":"9","key":"4527_CR29","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","volume":"28","author":"DC Danila","year":"2010","unstructured":"Danila DC, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28(9):1496\u2013501.","journal-title":"J Clin Oncol"},{"key":"4527_CR30","doi-asserted-by":"publisher","first-page":"mdt136","DOI":"10.1093\/annonc\/mdt136","volume":"24","author":"Y Loriot","year":"2013","unstructured":"Loriot Y, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013;24:mdt136.","journal-title":"Ann Oncol"},{"issue":"5","key":"4527_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, et al. Enzalutamide in metastatic prostate Cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333.","journal-title":"N Engl J Med"},{"issue":"4","key":"4527_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, et al. Abiraterone for prostate Cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u201351.","journal-title":"N Engl J Med"},{"issue":"4","key":"4527_CR33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate Cancer. N Engl J Med. 2017;377(4):352\u201360.","journal-title":"N Engl J Med"},{"key":"4527_CR34","unstructured":"South A, et al. Upfront docetaxel for men with prostate cancer: Medical Research Council Clinical Trials Unit, Univeristy of Central London; 2015. Available online. http:\/\/www.ctu.mrc.ac.uk\/13706\/13710\/docetaxel_prostate_cancer ."},{"key":"4527_CR35","unstructured":"The Royal College of Radiologists. Clinical Oncology UK Workforce Census 2015 Report. London: The Royal College of Radiologists; 2016. Available online https:\/\/www.rcr.ac.uk\/system\/files\/publication\/field_publication_files\/bfcr166_cr_census.pdf ."},{"key":"4527_CR36","unstructured":"National Institute for Health and Care Excellence., Docetaxel for the treatment of hormone refractory metastatic prostate cancer (TA101). 2006. Available online. https:\/\/www.nice.org.uk\/guidance\/ta101\/resources\/docetaxel-for-the-treatment-of-hormonerefractory-metastatic-prostate-cancer-pdf-82598007373765 ."},{"issue":"12","key":"4527_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009674","volume":"5","author":"J Bridges","year":"2015","unstructured":"Bridges J, et al. Cancer treatment decision-making processes for older patients with complex needs: a qualitative study. BMJ Open. 2015;5(12):e009674.","journal-title":"BMJ Open"},{"issue":"4","key":"4527_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.eururo.2015.09.013","volume":"69","author":"M Tucci","year":"2016","unstructured":"Tucci M, et al. Addition of Docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate Cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(4):563\u201373.","journal-title":"Eur Urol"},{"key":"4527_CR39","first-page":"S3","volume":"9","author":"MA Perlmutter","year":"2007","unstructured":"Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Reviews in urology. 2007;9:S3.","journal-title":"Reviews in urology"},{"issue":"3","key":"4527_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2010.03942.x","volume":"74","author":"EJ Hamilton","year":"2011","unstructured":"Hamilton EJ, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol. 2011;74(3):377\u201383.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"4527_CR41","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.eururo.2015.04.023","volume":"68","author":"L Bourke","year":"2015","unstructured":"Bourke L, et al. Survivorship and improving quality of life in men with prostate Cancer. Eur Urol. 2015;68(3):374\u201383.","journal-title":"Eur Urol"},{"issue":"28","key":"4527_CR42","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1200\/JCO.2006.08.2024","volume":"25","author":"KS Courneya","year":"2007","unstructured":"Courneya KS, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007;25(28):4396\u2013404.","journal-title":"J Clin Oncol"},{"issue":"17","key":"4527_CR43","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1200\/JCO.2014.59.1081","volume":"33","author":"H van Waart","year":"2015","unstructured":"van Waart H, et al. Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. J Clin Oncol. 2015;33(17):1918\u201327.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4527_CR44","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V90.9.3390","volume":"90","author":"F Dimeo","year":"1997","unstructured":"Dimeo F, et al. Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood. 1997;90(9):3390.","journal-title":"Blood"},{"issue":"7226","key":"4527_CR45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/bmj.320.7226.50","volume":"320","author":"N Mays","year":"2000","unstructured":"Mays N, Pope C. Qualitative research in health care: assessing quality in qualitative research. BMJ British Med J. 2000;320(7226):50\u20132.","journal-title":"BMJ British Med J"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4527-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4527-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4527-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T07:11:48Z","timestamp":1693725108000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4527-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4527"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4527-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"25 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol, topic guides and semi-structured interview schedules gained national NHS ethics approval by NRES Committee South West - Cornwall & Plymouth (15\/SW\/0260) and in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK. All Management permissions were sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. All participants gave written informed consent before participation in this study.Sustained exercise TrAining for Men wIth prostate caNcer on Androgen deprivation: the STAMINA programme (RP-DG-1213-10,010). REC Reference: 15\/SW\/0260 IRAS Project ID: 178340 Hospital ID: STH 18391 approved on 24\/08\/2015.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained for the use of anonymised verbatim quotes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"667"}}